This article emphasizes that patients presenting with COVID-19 infection especially presenting with predominantly gastrointestinal symptoms and a history of eating disorder or even other mental disorders should be evaluated thoroughly and differential diagnoses should be considered. Clinicians should keep in mind that eating disorders may happen after COVID infection or vaccination.
The aim of this study was to compare the severity of depression, impulsive behaviors and suicidal ideation in patients with obesity with Low Density Lipoprotein (LDL) below 100 or above 100 mg/dl.
Methods: This was a cross-sectional study. The study population included patients with obesity referred to the obesity clinic of Rasool-e-Akram Hospital affiliated to Iran University of Medical Sciences, Tehran, Iran. Patients were divided into two groups with LDL below and above 100 mg/dl. The Beck scale for suicidal ideation and Depression and the Barratt Impulsiveness Scale questionnaires were filled. Finally, the score of questionnaires and demographic variables were compared between the two groups. P-values below 0.05 were considered as statistically significant.
Results: 300 patients entered the study. There was a statistically significant difference regarding the severity of depression betweeen the two groups, as in patients with LDL over 100 mg/dl, depression was more severe (p-value = 0.02). Moreover, there was a statistically significant difference regarding the impulsivity score and its subgroups or the suicidal ideation between the two groups (higher in patients with LDL) above 100 mg/dl, p-values <0.05).
Conclusion: Elevated serum LDL levels could be associated with psychological factors such as depression or suicidal ideation and motor, cognition and unplanned impulsivity in patients with morbid obesity. This might be justified by an increase in BMI. Further clinical trials are required to assess these findings.
BackgroundIncreasing reports of manic episodes in patients during acute infection with COVID-19 have been documented since the pandemic began, including individuals without a previous personal or family history of bipolar disorder. As infections and autoimmunity have putative roles in bipolar disorder, we aimed to document the clinical presentations, associated stressors, family aggregation patterns, and brain imaging and electroencephalographic correlates with a series of patients with episodes of mania that emerged shortly after COVID-19 infections.MethodsWe obtained all relevant clinical information from 12 patients whose first manic episode started within a month of COVID-19 infection and were treated at Rasool-e-Akram hospital and Iran psychiatric hospital, two tertiary medical centers in Tehran, Iran, in 2021.ResultsPatients had a mean age of 44. The interval between the onset of symptoms of COVID and mania ranged between 0 and 28 days (mean: 16.25, median: 14 days); it was observed to be shorter in patients with a family history of mood disorders but not in those receiving corticosteroids. Alongside a descriptive overview of our sample, we provide detailed narrative descriptions of two of the cases for illustrative purposes and discuss our observations in the context of other cases reported elsewhere and the state-of-the-art regarding infectious diseases, COVID-19, and bipolar disorder as reported in previous literature.ConclusionOur case series documents observational and naturalistic evidence from a dozen of cases of mania in the context of acute COVID-19, which, while limited, calls for analytical research of the phenomenon, and points at a family history of bipolar disorder and the use of corticosteroids as factors for particular focus.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.